Jie Li1, Yulan Peng2, Yong Liu3, Wenwen Li3, Ya Jin2, Zhentao Tang3, Yixiang Duan4. 1. Research Center of Analytical Instrumentation, College of Chemistry, Sichuan University, Chengdu China. 2. Utrasonic Department of China West Hospital of Sichuan University, No 37, Guo Xue Road, Chengdu, China (610041). 3. Research Center of Analytical Instrumentation, Analytical and Testing Center, Sichuan University, Chengdu, China. 4. Research Center of Analytical Instrumentation, College of Chemistry, Sichuan University, Chengdu China; Research Center of Analytical Instrumentation, College of Life Science, Sichuan University, Chengdu China. Electronic address: yduan@scu.edu.cn.
Abstract
BACKGROUND: Breast cancer (BC) remains the most commonly diagnosed malignancy in women. We investigated 4 straight aldehydes in the exhaled breath as potential early BC diagnostic biomarkers. METHODS: End-tailed breath were collected by Bio-VOC® sampler and assayed by gas chromatography-mass spectrometry. Kruskal-Wallis one-way analysis of variance test and binary logistic regression were used for data analysis. The diagnostic accuracies were evaluated by receiver operating characteristic curves. A predictive model/equation was generated using the 4 biomarkers and validated by leave-one-out cross-validation. RESULTS: All four potential biomarkers demonstrated significant differences in concentrations between BC and healthy controls (HC) (p<0.05). The areas under the curves (AUCs) in HC vs BCI-II model using hexanal, heptanal, octanal, and nonanal were 0.816, 0.809, 0.731, and 0.830, respectively. The AUC for their combined use was 0.934 (sensitivity 91.7%, specificity 95.8%) in the early diagnosis of BC. The predictive model/equation exhibited good sensitivity (72.7%) and specificity (91.7%) in distinguishing between HC and BC (cross-validation: sensitivity 68.2% and specificity 91.7%). CONCLUSIONS: The diagnostic values of 4 exhaled straight aldehydes as early diagnostic biomarkers for BC were successfully verified and the diagnostic accuracy improved in their combined use.
BACKGROUND:Breast cancer (BC) remains the most commonly diagnosed malignancy in women. We investigated 4 straight aldehydes in the exhaled breath as potential early BC diagnostic biomarkers. METHODS: End-tailed breath were collected by Bio-VOC® sampler and assayed by gas chromatography-mass spectrometry. Kruskal-Wallis one-way analysis of variance test and binary logistic regression were used for data analysis. The diagnostic accuracies were evaluated by receiver operating characteristic curves. A predictive model/equation was generated using the 4 biomarkers and validated by leave-one-out cross-validation. RESULTS: All four potential biomarkers demonstrated significant differences in concentrations between BC and healthy controls (HC) (p<0.05). The areas under the curves (AUCs) in HC vs BCI-II model using hexanal, heptanal, octanal, and nonanal were 0.816, 0.809, 0.731, and 0.830, respectively. The AUC for their combined use was 0.934 (sensitivity 91.7%, specificity 95.8%) in the early diagnosis of BC. The predictive model/equation exhibited good sensitivity (72.7%) and specificity (91.7%) in distinguishing between HC and BC (cross-validation: sensitivity 68.2% and specificity 91.7%). CONCLUSIONS: The diagnostic values of 4 exhaled straight aldehydes as early diagnostic biomarkers for BC were successfully verified and the diagnostic accuracy improved in their combined use.
Authors: Agne Krilaviciute; Jonathan Alexander Heiss; Marcis Leja; Juozas Kupcinskas; Hossam Haick; Hermann Brenner Journal: Oncotarget Date: 2015-11-17